CHMP Adopts Positive Opinion for Pepaxti (melflufen); Recommends Label Expansion to Earlier Lines of Treatment for Lenalidomide-Refractory Myeloma  (https://www.myeloma.org/news-events/multiple-myeloma-news/chmp-positive-opinion-melflufen-lenalidomide-refractory-myeloma)